CSIMarket
 


Quidel Corporation  (QDEL)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

QDEL's Operating Income Growth by Quarter and Year

Quidel's Operating Income results by quarter and year




QDEL Operating Income (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 617.08 35.06 27.54
III Quarter September - 307.96 20.68 16.89
II Quarter June 23.31 83.66 5.82 0.40
I Quarter March 224.19 51.63 31.15 51.09
FY   247.50 1,060.33 92.71 95.92



QDEL Operating Income second quarter 2021 Y/Y Growth Comment
Quidel Corporation reported drop in Operating Income in the second quarter by -72.14% to $ 23.31 millions, from the same quarter in 2020.
The fall in the second quarter Quidel Corporation's Operating Income compares unfavorably to the Company's average Operating Income jump of 57.83%.

Looking into second quarter results within Biotechnology & Drugs industry 10 other companies have achieved higher Operating Income growth. While Quidel Corporation' s Operating Income meltdown of -72.14% ranks overall at the positon no. 1467 in the second quarter.

Explain Operating Income growth


QDEL Operating Income ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 1660.07 % 27.31 % 607.97 %
III Quarter September - 1389.17 % 22.44 % -
II Quarter June -72.14 % 1337.46 % 1355 % -
I Quarter March 334.22 % 65.75 % -39.03 % 165.68 %
FY   - 1043.71 % -3.35 % 904.4 %

Financial Statements
Quidel's second quarter 2021 Operating Income $ 23.31 millions QDEL's Income Statement
Quidel's second quarter 2020 Operating Income $ 83.66 millions Quarterly QDEL's Income Statement
New: More QDEL's historic Operating Income Growth >>


QDEL Operating Income (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 100.38 % 69.54 % 63.06 %
III Quarter September - 268.11 % 255.33 % 4122.5 %
II Quarter June -89.6 % 62.04 % -81.32 % -99.22 %
I Quarter March -63.67 % 47.26 % 13.11 % 1213.37 %
FY (Year on Year)   - 1043.71 % -3.35 % 904.4 %




Operating Income second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #11
Healthcare Sector #97
Overall #1467

Operating Income Y/Y Growth Statistics
High Average Low
619.97 % 57.83 % -83.59 %
(Sep. 30, 2015)   (March 31, 2014)
Operating Income second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #11
Healthcare Sector #97
Overall #1467
Operating Income Y/Y Growth Statistics
High Average Low
619.97 % 57.83 % -83.59 %
(Sep. 30, 2015)   (March 31, 2014)

Operating Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Quidel's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
4081.68 % 334.34 % -99.21 %
(Sep 30 2018)  


QDEL's II. Quarter Q/Q Operating Income Comment
In the II. Quarter 2021 Quidel Corporation disclosed fall in Operating Income from the first quarter by -89.6% to $ 23.31 millions, from $ 224.19 millions declared in the previous quarter.

Although periodic circumstance normally elevate II. Quarter 2021 performance, that simply has not been substantial to salvage QDEL's outcome, Theodor Eriksson, an industry consultant located in Frankfurt pointed out.

Within Biotechnology & Drugs industry 24 other companies have achieved higher Operating Income quarter on quarter growth. While Quidel's Operating Income growth quarter on quarter, overall rank is 2337.


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #25
Healthcare Sector #178
Overall #2337
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #25
Healthcare Sector #178
Overall #2337
Operating Income Q/Q Growth Statistics
High Average Low
4081.68 % 334.34 % -99.21 %
(Sep 30 2018)  


QDEL's II. Quarter Q/Q Operating Income Comment
In the II. Quarter 2021 Quidel Corporation realized fall in Operating Income sequentially by -89.6% to $ 23.31 millions, from $ 224.19 millions declared a quarter before.

Some periodic circumstance could not salvage the II. Quarter for the Quidel Corporation, Theodor Eriksson, an industry consultant located in Frankfurt wrote, he voiced little pessimism conserning Quidel's outlook, he detected additional challenges down the road for QDEL and mentioned that average quarter on quarter Operating Income growth is at 334.34% for QDEL.

Within Biotechnology & Drugs industry 24 other companies have achieved higher Operating Income quarter on quarter growth. While Quidel's Operating Income growth quarter on quarter, overall rank is 2337.


Quidel's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
Cumulative Operating Income 12 Months Ending $ 1,172.53 $ 1,232.89 $ 1,060.33 $ 478.31 $ 191.04
Y / Y Operating Income Growth (TTM) 513.77 % 989.21 % 1043.63 % 461.46 % 134.68 %
Year on Year Operating Income Growth Overall Ranking # 69 # 41 # 17 # 61 # 149
Seqeuential Operating Income Change (TTM) -4.9 % 16.27 % 121.68 % 150.38 % 68.77 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1467 # 884 # 39 # 64 # 123




Cumulative Operating Income growth Comment
Assuming the Quidel's fiscal year would have ended in Jun 30 2021, Quidel would have reprted above average annual Operating Income surge of 513.77% year on year, of $ 1,173 millions.
This marks a slow-down of the companys growth trends and from the 989.21% surge in Mar 31 2021.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 41 to 69.

Operating Income TTM Q/Q Growth Statistics
High Average Low
619.97 %
57.83 %
-83.59 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 11
Healthcare Sector # 5
Overall # 69

Operating Income TTM Y/Y Growth Statistics
High Average Low
1043.63 %
313.3 %
-63.83 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 97
S&P 500 # 1467
Cumulative Operating Income growth Comment
Assuming the Quidel's fiscal year would have ended in Jun 30 2021, Quidel would have reprted above average annual Operating Income surge of 513.77% year on year, of $ 1,173 millions.
This marks a slow-down of the companys growth trends and from the 989.21% surge in Mar 31 2021.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 41 to 69.

Operating Income TTM Q/Q Growth Statistics
High Average Low
619.97 %
57.83 %
-83.59 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 11
Healthcare Sector # 5
Overall # 69

Operating Income TTM Y/Y Growth Statistics
High Average Low
1043.63 %
313.3 %
-63.83 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 97
S&P 500 # 1467




Other Operating Income Growth
Biotechnology & Drugs Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
QDEL's Operating Income Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for QDEL's Competitors
Operating Income Growth for Quidel's Suppliers
Operating Income Growth for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Dividend Payout Ratio
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons



Companies with similar Operating Income surge for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Jun 30 2021
Collegium Pharmaceutical inc -0.85%$ -0.846 millions
Atrion Corporation-2.50%$ -2.499 millions
Insulet Corporation-4.36%$ -4.364 millions
Endo International Plc-4.94%$ -4.941 millions
Zynex Inc-6.61%$ -6.610 millions
Tenax Therapeutics Inc-8.37%$ -8.374 millions
Corcept Therapeutics Inc-9.41%$ -9.412 millions
Pacific Health Care Organization Inc-11.14%$ -11.143 millions
Diversified Healthcare Trust-15.07%$ -15.072 millions
Neurocrine Biosciences Inc -18.02%$ -18.016 millions
Lhc Group Inc-18.49%$ -18.485 millions
Co diagnostics Inc -19.83%$ -19.833 millions
Accuray Incorporated-20.76%$ -20.758 millions
Chemed Corporation-22.70%$ -22.705 millions
Supernus Pharmaceuticals inc -25.11%$ -25.105 millions
Msa Safety Inc-27.42%$ -27.424 millions
Reynolds Consumer Products Inc -30.41%$ -30.409 millions
Tivity Health Inc -32.60%$ -32.602 millions
Hill rom Holdings Inc -33.92%$ -33.925 millions
Tempest Therapeutics Inc -36.01%$ -36.015 millions
Fourth Wave Energy Inc -37.29%$ -37.292 millions
Incyte Corp-38.97%$ -38.972 millions
The Pennant Group Inc -41.25%$ -41.251 millions
Petmed Express Inc-42.57%$ -42.571 millions
Healthcare Services Group Inc -47.56%$ -47.556 millions
Hanger inc -48.29%$ -48.293 millions
Merck and Co Inc -48.42%$ -48.418 millions
Regional Health Properties Inc -49.31%$ -49.306 millions
Electromed Inc -49.51%$ -49.511 millions
Molecular Templates Inc -50.15%$ -50.145 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TCRX's Profile

Stock Price

TCRX's Financials

Business Description

Fundamentals

Charts & Quotes

TCRX's News

Suppliers

TCRX's Competitors

Customers & Markets

Economic Indicators

TCRX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071